Backgrund: -Hepcidin is acute phase reactant protein produced in the liver discovered to be a key regulator of iron homeostasis. It increases by inflammation andlimits iron availability for erythropoiesis in chronic kidney disease.Objectives:-is to assess hepcidin level in Chronic Kidney Disease patients and its relation to iron level and erythropoiesis. Hepcidin may be a new biomarker of iron status.Methods:-Complete blood count, total iron profile, SerumHepcidin level for 30 patients withstage V chronic kidney disease on regular haemodialysis.Ten age and sex matched normal controls were included in the study.Results:-Highly significant difference between cases and controls as regards to Hepcidin level being higher among cases than controls .and significant negative correlation between Hepcidin level and the Hemoglobin level, and highly significant positive correlation between Hepcidin level and each of serum Iron level and serum Ferritin. And mean Hepcidin level was highly significantly higher among cases who received blood transfusion than those who didn’t receive blood transfusion.Conclusions:-Hepcidin is thought to be the major regulator of dietary iron absorption and cellular iron release.Our study suggests that hepcidin is primarily associated with iron stores and may also be involved in regulating iron availability for erythropoiesis in Hemodialysis patients. Increased hepcidin across the spectrum of CKD may contribute to abnormal iron regulation and erythropoiesis and may be a novel biomarker of iron status and erythropoietin resistance.